Victoria L. Gadd, Richard Skoien, Elizabeth E. Powell, Kevin J. Fagan, Clay Winterford, Leigh Horsfall, Katharine Irvine, Andrew D. Clouston – 20 November 2013 – Although nonalcoholic fatty liver disease (NAFLD) is conventionally assessed histologically for lobular features of inflammation, development of portal fibrosis appears to be associated with disease progression. We investigated the composition of the portal inflammatory infiltrate and its relationship to the ductular reaction (DR), a second portal phenomenon implicated in fibrogenesis.

Len Verbeke, Ricard Farre, Jonel Trebicka, Mina Komuta, Tania Roskams, Sabine Klein, Ingrid Vander Elst, Petra Windmolders, Tim Vanuytsel, Frederik Nevens, Wim Laleman – 20 November 2013 – The farnesoid X receptor (FXR) is a nuclear bile acid receptor involved in bile acid homeostasis, hepatic and intestinal inflammation, liver fibrosis, and cardiovascular disease.

Morris Sherman – 20 November 2013

John T. Skamarauskas, Fiona Oakley, Fiona E. Smith, Carlo Bawn, Michael Dunn, Daniel S. Vidler, Matthew Clemence, Peter G. Blain, Roy Taylor, Michael P. Gamcsik, Peter E. Thelwall – 16 November 2013 – Oxidative stress (OS) plays a central role in the progression of liver disease and in damage to liver by toxic xenobiotics. We have developed methods for noninvasive assessment of hepatic OS defenses by measuring flux through the glutathione (GSH) synthesis pathway. 13C‐labeled GSH is endogenously produced and detected by in vivo magnetic resonance after administration of [2‐13C]‐glycine.

Deok‐Bog Moon, Sung‐Gyu Lee, Jung‐Man Namkoong, Shin Hwang, Ki‐Hun Kim, Chul‐Soo Ahn, Tae‐Yong Ha, Gi‐Won Song, Dong‐Hwan Jung, Gil‐Chun Park, Yo‐Han Park, Hyung‐Woo Park, Bo‐Hyun Jung, Sung‐Hwa Kang – 15 November 2013

Jessica Howell, Paul Gow, Peter Angus, Kumar Visvanathan – 15 November 2013 – Toll‐like receptors (TLRs) are pathogen recognition receptors that orchestrate the innate immune response and the subsequent adaptive immune response. TLRs can be triggered by exogenous ligands expressed by invading pathogens or by the release of endogenous ligands, such as that occurring through cellular injury during the transplantation process.

Li Jiang, Anque Liao, Lunan Yan, Jiayin Yang – 15 November 2013

Yusuf Gunay, Necdet Guler, Murat Dayangac, Fatih Taskesen, Onur Yaprak, Ertan Emek, Murat Akyildiz, Gulum Altaca, Yildiray Yuzer, Yaman Tokat – 15 November 2013 – Living donor liver transplantation (LDLT) is an accepted option for end‐stage liver disease, particularly in countries in which there are organ shortages. However, little is known about LDLT for obese patients. We sought to determine the effects of obesity on pretransplant living donor selection for obese recipients and their outcomes.

Yunching Chen, Yuhui Huang, Thomas Reiberger, Annique M. Duyverman, Peigen Huang, Rekha Samuel, Lotte Hiddingh, Sylvie Roberge, Christina Koppel, Gregory Y. Lauwers, Andrew X. Zhu, Rakesh K. Jain, Dan G. Duda – 14 November 2013 – Sorafenib—a broad kinase inhibitor—is a standard therapy for advanced hepatocellular carcinoma (HCC) and has been shown to exert antifibrotic effects in liver cirrhosis, a precursor of HCC. However, the effects of sorafenib on tumor desmoplasia—and its consequences on treatment resistance—remain unknown.

Jian Sun, Qing Xie, Deming Tan, Qin Ning, Junqi Niu, Xuefan Bai, Rong Fan, Shijun Chen, Jun Cheng, Yanyan Yu, Hao Wang, Min Xu, Guangfeng Shi, Mobin Wan, Xinyue Chen, Hong Tang, Jifang Sheng, Xiaoguang Dou, Junping Shi, Hong Ren, Maorong Wang, Hongfei Zhang, Zhiliang Gao, Chengwei Chen, Hong Ma, Jidong Jia, Jinlin Hou – 14 November 2013 – An optimization strategy based on the Roadmap concept is supposed to improve the clinical outcomes of patients with suboptimal antiviral response. The aim of this study was to prove the concept with a multicenter, open‐label, randomized, controlled study.